{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T23:31:28Z","timestamp":1790983888581,"version":"4.1.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,4,3]],"date-time":"2023-04-03T00:00:00Z","timestamp":1680480000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,3]],"date-time":"2023-04-03T00:00:00Z","timestamp":1680480000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>vasopressin is commonly used as a second-line vasopressor for patients with septic shock, but the optimal timing of initiation is uncertain. This study was designed to investigate when vasopressin initiation may be beneficial for 28-day mortality in septic shock patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This was a retrospective observational cohort study from the MIMIC-III v1.4 and MIMIC-IV v2.0 databases. All adults diagnosed with septic shock according to Sepsis-3 criteria were included. Patients were stratified into two groups based on norepinephrine (NE) dose at the time of vasopressin initiation, defined as the low doses of NE group (NE&lt;0.25\u00a0\u00b5g\/kg\/min) and the high doses of NE group (NE\u2009\u2265\u20090.25\u00a0\u00b5g\/kg\/min). The primary end\u2010point was 28\u2010day mortality after diagnosis of septic shock. The analysis involved propensity score matching (PSM), multivariable logistic regression, doubly robust estimation, the gradient boosted model, and an inverse probability\u2010weighting model.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 1817 eligible patients were included in our original cohort (613 in the low doses of NE group and 1204 in the high doses of NE group). After 1:1 PSM, 535 patients from each group with no difference in disease severity were included in the analysis. The results showed that vasopressin initiation at low doses of NE was associated with reduced 28-day mortality (odds ratio [OR] 0.660, 95% confidence interval [CI] 0.518\u20130.840, p\u2009&lt;\u20090.001). Compared with patients in the high doses of NE group, patients in the low doses of NE group received significantly shorter duration of NE, with less intravenous fluid volume on the first day after initiation of vasopressin, more urine on the second day, and longer mechanical ventilation-free days and CRRT-free days. Nevertheless, there were no significant differences in hemodynamic response to vasopressin, duration of vasopressin, and ICU or hospital length of stay.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Among adults with septic shock, vasopressin initiation when low-dose NE was used was associated with an improvement in 28-day mortality.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12879-023-08147-6","type":"journal-article","created":{"date-parts":[[2023,4,3]],"date-time":"2023-04-03T12:27:10Z","timestamp":1680524830000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Timing of vasopressin initiation and mortality in patients with septic shock: analysis of the MIMIC-III and MIMIC-IV databases"],"prefix":"10.1186","volume":"23","author":[{"given":"Jun","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongliu","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,3]]},"reference":[{"key":"8147_CR1","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1001\/jama.2016.0287","volume":"315","author":"M Singer","year":"2016","unstructured":"Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The Third International Consensus Definitions for Sepsis and septic shock (Sepsis-3). JAMA. 2016;315:801.","journal-title":"JAMA"},{"key":"8147_CR2","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1186\/s13054-020-02950-2","volume":"24","author":"M Bauer","year":"2020","unstructured":"Bauer M, Gerlach H, Vogelmann T, Preissing F, Stiefel J, Adam D. Mortality in sepsis and septic shock in Europe, North America and Australia between 2009 and 2019\u2014 results from a systematic review and meta-analysis. Crit Care. 2020;24:239.","journal-title":"Crit Care"},{"key":"8147_CR3","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1007\/s00134-021-06506-y","volume":"47","author":"L Evans","year":"2021","unstructured":"Evans L, Rhodes A, Alhazzani W, Antonelli M, Coopersmith CM, French C, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. Intensive Care Med. 2021;47:1181\u2013247.","journal-title":"Intensive Care Med"},{"key":"8147_CR4","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1038\/nrneph.2016.144","volume":"12","author":"J-L Vincent","year":"2016","unstructured":"Vincent J-L, Post EH. Vasopressin: a first-line agent for septic shock? Nat Rev Nephrol. 2016;12:718\u20139.","journal-title":"Nat Rev Nephrol"},{"key":"8147_CR5","doi-asserted-by":"crossref","unstructured":"Vail EA, Gershengorn HB, Hua M, Walkey AJ, Wunsch H. Epidemiology of Vasopressin Use for Adults with Septic Shock.Annals ATS. 2016;:AnnalsATS.201604-259OC.","DOI":"10.1513\/AnnalsATS.201604-259OC"},{"key":"8147_CR6","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1097\/00003246-199708000-00012","volume":"25","author":"DW Landry","year":"1997","unstructured":"Landry DW, Levin HR, Gallant EM, Seo S, D\u2019Alessandro D, Oz MC, et al. Vasopressin pressor hypersensitivity in vasodilatory septic shock. Crit Care Med. 1997;25:1279\u201382.","journal-title":"Crit Care Med"},{"key":"8147_CR7","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1097\/00000542-200203000-00011","volume":"96","author":"BM Patel","year":"2002","unstructured":"Patel BM, Walley KR. Beneficial Effects of short-term vasopressin infusion during severe septic shock. Anesthesiology. 2002;96:7.","journal-title":"Anesthesiology"},{"key":"8147_CR8","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.jss.2015.07.016","volume":"200","author":"X Xiao","year":"2016","unstructured":"Xiao X, Zhang J, Wang Y, Zhou J, Zhu Y, Jiang D, et al. Effects of terlipressin on patients with sepsis via improving tissue blood flow. J Surg Res. 2016;200:274\u201382.","journal-title":"J Surg Res"},{"key":"8147_CR9","doi-asserted-by":"crossref","unstructured":"Russell JA, H\u00e9bert PC, Granton JT, Ayers D. Vasopressin versus Norepinephrine Infusion in Patients with Septic Shock.n engl j med. 2008;:11.","DOI":"10.1056\/NEJMoa067373"},{"key":"8147_CR10","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1001\/jama.2016.10485","volume":"316","author":"AC Gordon","year":"2016","unstructured":"Gordon AC, Mason AJ, Thirunavukkarasu N, Perkins GD, Cecconi M, Cepkova M, et al. Effect of early vasopressin vs norepinephrine on kidney failure in patients with septic shock: the VANISH Randomized Clinical Trial. JAMA. 2016;316:509.","journal-title":"JAMA"},{"key":"8147_CR11","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1007\/s00134-019-05620-2","volume":"45","author":"M Nagendran","year":"2019","unstructured":"Nagendran M, Russell JA, Walley KR, Brett SJ, Perkins GD, Hajjar L, et al. Vasopressin in septic shock: an individual patient data meta-analysis of randomised controlled trials. Intensive Care Med. 2019;45:844\u201355.","journal-title":"Intensive Care Med"},{"key":"8147_CR12","doi-asserted-by":"crossref","unstructured":"Huang H. The effect of early vasopressin use on patients with septic shock: A systematic review and meta-analysis.American Journal of Emergency Medicine. 2021;:6.","DOI":"10.21203\/rs.3.rs-99744\/v1"},{"key":"8147_CR13","doi-asserted-by":"crossref","unstructured":"Sacha GL, Lam SW, Wang L, Duggal A, Reddy AJ, Bauer SR. Association of Catecholamine Dose, Lactate, and Shock Duration at Vasopressin Initiation With Mortality in Patients With Septic Shock.Critical Care Medicine. 2021;Publish Ahead of Print.","DOI":"10.1097\/CCM.0000000000005317"},{"key":"8147_CR14","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s13054-022-03911-7","volume":"26","author":"PM Wieruszewski","year":"2022","unstructured":"Wieruszewski PM, Khanna AK. Vasopressor choice and timing in vasodilatory shock. Crit Care. 2022;26:76.","journal-title":"Crit Care"},{"key":"8147_CR15","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/s13054-022-04001-4","volume":"26","author":"P Guerci","year":"2022","unstructured":"Guerci P, Belveyre T, Mongardon N, Novy E. When to start vasopressin in septic shock: the strategy we propose. Crit Care. 2022;26:125.","journal-title":"Crit Care"},{"key":"8147_CR16","doi-asserted-by":"publisher","first-page":"160035","DOI":"10.1038\/sdata.2016.35","volume":"3","author":"AEW Johnson","year":"2016","unstructured":"Johnson AEW, Pollard TJ, Shen L, Lehman LH, Feng M, Ghassemi M, et al. MIMIC-III, a freely accessible critical care database. Sci Data. 2016;3:160035.","journal-title":"Sci Data"},{"key":"8147_CR17","unstructured":"Johnson A, Pollard T, Mark R. MIMIC-III Clinical Database CareVue subset (version 1.4). PhysioNet. 2022."},{"key":"8147_CR18","unstructured":"Johnson A, Bulgarelli L, Pollard T, Horng S, Celi LA, Mark R. MIMIC-IV (version 2.0). PhysioNet. 2022."},{"key":"8147_CR19","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1093\/aje\/kwn164","volume":"168","author":"SR Cole","year":"2008","unstructured":"Cole SR, Hernan MA. Constructing inverse probability weights for marginal structural models. Am J Epidemiol. 2008;168:656\u201364.","journal-title":"Am J Epidemiol"},{"key":"8147_CR20","doi-asserted-by":"publisher","first-page":"3388","DOI":"10.1002\/sim.5753","volume":"32","author":"DF McCaffrey","year":"2013","unstructured":"McCaffrey DF, Griffin BA, Almirall D, Slaughter ME, Ramchand R, Burgette LF. A tutorial on propensity score estimation for multiple treatments using generalized boosted models. Statist Med. 2013;32:3388\u2013414.","journal-title":"Statist Med"},{"key":"8147_CR21","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1093\/aje\/kwq439","volume":"173","author":"MJ Funk","year":"2011","unstructured":"Funk MJ, Westreich D, Wiesen C, St\u00fcrmer T, Brookhart MA, Davidian M. Doubly robust estimation of Causal Effects. Am J Epidemiol. 2011;173:761\u20137.","journal-title":"Am J Epidemiol"},{"key":"8147_CR22","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1177\/0885066617725255","volume":"34","author":"DA Hammond","year":"2019","unstructured":"Hammond DA, Cullen J, Painter JT, McCain K, Clem OA, Brotherton AL, et al. Efficacy and safety of the early addition of Vasopressin to Norepinephrine in Septic Shock. J Intensive Care Med. 2019;34:910\u20136.","journal-title":"J Intensive Care Med"},{"key":"8147_CR23","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1002\/phar.2105","volume":"38","author":"DA Hammond","year":"2018","unstructured":"Hammond DA, Ficek OA, Painter JT, McCain K, Cullen J, Brotherton AL, et al. Prospective open-label trial of early concomitant vasopressin and norepinephrine therapy versus initial norepinephrine monotherapy in septic shock. Pharmacotherapy. 2018;38:531\u20138.","journal-title":"Pharmacotherapy"},{"key":"8147_CR24","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1001\/jama.2018.4528","volume":"319","author":"WF McIntyre","year":"2018","unstructured":"McIntyre WF, Um KJ, Alhazzani W, Lengyel AP, Hajjar L, Gordon AC, et al. Association of Vasopressin Plus Catecholamine Vasopressors vs catecholamines alone with Atrial Fibrillation in patients with distributive shock: a systematic review and Meta-analysis. JAMA. 2018;319:1889.","journal-title":"JAMA"},{"key":"8147_CR25","doi-asserted-by":"publisher","first-page":"563","DOI":"10.3389\/fphar.2020.00563","volume":"11","author":"R Yao","year":"2020","unstructured":"Yao R, Xia D, Wang L, Wu G, Zhu Y, Zhao H, et al. Clinical efficiency of Vasopressin or its analogs in comparison with catecholamines alone on patients with septic shock: a systematic review and Meta-analysis. Front Pharmacol. 2020;11:563.","journal-title":"Front Pharmacol"},{"key":"8147_CR26","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1007\/s00134-019-05642-w","volume":"45","author":"PJ Young","year":"2019","unstructured":"Young PJ, Delaney A, Venkatesh B. Vasopressin in septic shock: what we know and where to next? Intensive Care Med. 2019;45:902\u20133.","journal-title":"Intensive Care Med"},{"key":"8147_CR27","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1001\/jama.2019.5791","volume":"321","author":"CW Seymour","year":"2019","unstructured":"Seymour CW, Kennedy JN, Wang S, Chang C-CH, Elliott CF, Xu Z, et al. Derivation, validation, and potential treatment implications of Novel Clinical Phenotypes for Sepsis. JAMA. 2019;321:2003.","journal-title":"JAMA"},{"key":"8147_CR28","doi-asserted-by":"publisher","first-page":"644195","DOI":"10.3389\/fmed.2021.644195","volume":"8","author":"K Nakamura","year":"2021","unstructured":"Nakamura K, Nakano H, Naraba H, Mochizuki M, Takahashi Y, Sonoo T, et al. Vasopressin loading for refractory septic shock: a preliminary analysis of a Case Series. Front Med. 2021;8:644195.","journal-title":"Front Med"},{"key":"8147_CR29","doi-asserted-by":"crossref","unstructured":"Scheibner A, Betthauser KD, Bewley AF, Juang P, Lizza B, Micek S et al. Machine learning to predict vasopressin responsiveness in patients with septic shock.Pharmacotherapy. 2022;:phar.2683.","DOI":"10.1002\/phar.2683"},{"key":"8147_CR30","doi-asserted-by":"crossref","unstructured":"Jakowenko ND, Murata J, Kopp BJ, Erstad BL. Influence of Timing and Catecholamine Requirements on Vasopressin Responsiveness in Critically ill Patients with Septic Shock.J Intensive Care Med. 2022;:088506662210818.","DOI":"10.1177\/08850666221081836"},{"key":"8147_CR31","doi-asserted-by":"publisher","first-page":"e0634","DOI":"10.1097\/CCE.0000000000000634","volume":"4","author":"SR Bauer","year":"2022","unstructured":"Bauer SR, Sacha GL, Siuba MT, Lam SW, Reddy AJ, Duggal A, et al. Association of arterial pH with hemodynamic response to Vasopressin in patients with septic shock: an Observational Cohort Study. Crit Care Explorations. 2022;4:e0634.","journal-title":"Crit Care Explorations"},{"key":"8147_CR32","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s13613-018-0379-5","volume":"8","author":"GL Sacha","year":"2018","unstructured":"Sacha GL, Lam SW, Duggal A, Torbic H, Bass SN, Welch SC, et al. Predictors of response to fixed-dose vasopressin in adult patients with septic shock. Ann Intensive Care. 2018;8:35.","journal-title":"Ann Intensive Care"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-023-08147-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-023-08147-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-023-08147-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,3]],"date-time":"2023-04-03T12:27:17Z","timestamp":1680524837000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-023-08147-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,3]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["8147"],"URL":"https:\/\/doi.org\/10.1186\/s12879-023-08147-6","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,3]]},"assertion":[{"value":"11 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The dataset in this study was obtained from MIMIC-III v1.4 and MIMIC-IV v2.0. We had completed the CITI Program course known as Human Research and Data or Specimens Only Research to apply for permission to access the database (Record ID: 48615099). The individual information of the patients included in this database was anonymous, and ethical review and informed consent were waived. All methods were performed in accordance with the relevant guidelines and regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"199"}}